Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

november-december, 2024
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Quality / GMP

US FDA assigns VAI classification to Jubilant Pharmova's API facility at Nanjangud

US FDA assigns VAI classification to Jubilant Pharmova's API facility at Nanjangud

Jubilant Pharmova announced that under the United States Food and Drug Administration (US FDA) inspection of its API manufacturing facility at Nanjangud during December 5 to 13, 2022, it received a communication from the USFDA through which the regulatory agency assigned the inspection classification of the API facility as "Voluntary Action Indicated (VAI)."

Based on this inspection and the USFDA VAI classification, this facility complies concerning current good manufacturing practices (cGMP).
Read more on:
Jubilant Pharmanova USFDA VAI
More news about: quality / gmp | Published by Sudeep Soparkar | March - 11 - 2023 | 302

Last news about this category

LGM Pharma Expands Analytical Testing Services with New Services LGM Pharma Expands Analytical Testing Services with New Services
Avery Dennison Rolls Out AD Minidose U9XM to Ensure Authenticity of Pharma Devices Avery Dennison Rolls Out AD Minidose U9XM to Ensure Authenticity of Pharma Devices
eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
Gritgen Therapeutics Launches Operations at Commercial GMP Facility in China Gritgen Therapeutics Launches Operations at Commercial GMP Facility in China
Aurisco's Manufacturing Site in China Clears FDA Inspection Aurisco's Manufacturing Site in China Clears FDA Inspection
Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC) Marksans receives USFDA approval for Guaifenesin Extended-Release Tablets (OTC)
Concord Biotech Limited receives EIR for Unit III Concord Biotech Limited receives EIR for Unit III
Successful FDA inspection at Auriscos manufacturing site in Yangzhou, China Successful FDA inspection at Auriscos manufacturing site in Yangzhou, China
Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations Lupins Mandideep Unit-2 Facility Completes U.S. FDA Inspection with No Observations
Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA Dr. Reddys API plant in Hyderabad gets EIR from U.S. FDA
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy